| Title |
Combination of Dabrafenib and Trametinib for the treatment of relapsed and refractory multiple myeloma harboring BRAF V600E mutation |
| Authors |
Čepulytė, Rūta ; Žučenka, Andrius ; Pečeliūnas, Valdas |
| DOI |
10.1155/2020/8894031 |
| Full Text |
|
| Is Part of |
Case reports in hematology.. London : Hindawi Ltd. 2020, vol. 2020, art. no. 8894031, p. [1-5].. ISSN 2090-6560. eISSN 2090-6579 |
| Keywords [eng] |
multiple myeloma ; heterogeneity ; RAF inhibitors |
| Abstract [eng] |
Multiple myeloma (MM) is an incurable plasma cell neoplasia characterized by relapsed and/or refractory (R/R) disease course, which poses a major therapeutic challenge. New therapies, including BRAF V600E mutation targeting, may become a new treatment option for R/R MM. In combination with mitogen-activated protein kinase inhibitors (MEKi), BRAF inhibitors (BRAFi) could provide better tailored clinical management, although experience in this field is lacking. To this date, there is only one case describing R/R MM treatment with BRAFi vemurafenib and MEKi cobimetinib. This is the first case presenting a R/R MM patient treated with BRAFi dabrafenib and MEKi trametinib. |
| Published |
London : Hindawi Ltd |
| Type |
Journal article |
| Language |
English |
| Publication date |
2020 |
| CC license |
|
